Current Status in Rechallenge of Immunotherapy

International Journal of Biological Sciences, Journal Year: 2023, Volume and Issue: 19(8), P. 2428 - 2442

Published: Jan. 1, 2023

The treatment of malignant tumors has entered the era immunotherapy, and immune checkpoint inhibitors (ICIs) have brought significant benefits to patients.However, some patients are required discontinue with ICIs owing factors such as disease progression intolerable side effects.Faced limited subsequent options complex medical needs, we searched PubMed, Embase, Cochrane library, NIH clinical trials database found that ICI rechallenge could be a relevant strategy.The affect efficacy include patients' characteristics, therapeutic strategy selection, timing treatment.Multiple used identify target population, which features PD-L1 expression more potential.Both single combination therapy may survival benefits.Patients who tolerated initial immunotherapy well undergo rechallenge, while experienced grade 3 or higher immune-related adverse events should carefully assessed prior rechallenge.Interventions interval between two courses will clearly an impact on treatment.Preliminary data evaluation supports further investigation contribute its efficacy.

Language: Английский

---

Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 167, P. 115514 - 115514

Published: Sept. 15, 2023

Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and constitutively expressed on surface of immune cells. As a receptor checkpoint, PD-1 can bind to programmed ligand-1/programmed ligand-2 (PD-L1/PD-L2) in tumor cells, leading evasion. Anti-PD-1 anti-PD-L1 are important components therapy. as an intrinsic variant (iPD-1) cancer cells where it plays roles malignant progression proposed recent studies. However, iPD-1 has received much less attention compared although there unmet medical need for fully elucidating mechanisms actions achieve best response immunotherapy. suppresses tumorigenesis non-small lung (NSCLC) colon cancer, whereas promotes melanoma, hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC), thyroid (TC), glioblastoma (GBM), triple-negative breast (TNBC). In this review, we focus role development its molecular mechanisms. We deeply discuss nivolumab-based combined therapy common may explain different therapeutic effects anti-PD-1 treatment provide critical information use anti-tumor approaches.

Language: Английский

---

Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations

Translational Oncology, Journal Year: 2023, Volume and Issue: 40, P. 101851 - 101851

Published: Dec. 1, 2023

Colorectal cancer (CRC) is the third most prevalent in world. The PD-1/PD-L1 pathway plays a crucial role modulating immune response to cancer, and PD-L1 expression has been observed tumor cells within microenvironment of CRC. Thus, immunotherapy drugs, specifically checkpoint inhibitors, have developed target signaling pathway, thereby inhibiting interaction between PD-1 restoring T-cell function cells. However, emergence resistance mechanisms can reduce efficacy these treatments. To counter this, monoclonal antibodies (mAbs) used improve CRC mAbs such as nivolumab pembrolizumab are currently approved for treatment. These impede receptors, including PD-1/PD-L1, their combination therapy shows promise treatment advanced This review presents concise overview use blockade therapeutic strategy using therapies. Additionally, this article outlines an suppressor well potential advantages administering inflammatory agents Finally, analyzes outcomes clinical trials examine challenges anti-PD-1/PD-L1 resistance.

Language: Английский

---

Ti3C2Tx MXene -facilitated non-selective trapping effect: Efficient SERS detection of exosomal PD-L1

Biosensors and Bioelectronics, Journal Year: 2023, Volume and Issue: 237, P. 115493 - 115493

Published: June 21, 2023

Language: Английский

---

Enhancing cancer immunotherapy with photodynamic therapy and nanoparticle: making tumor microenvironment hotter to make immunotherapeutic work better

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: April 5, 2024

Cancer immunotherapy has made tremendous advancements in treating various malignancies. The biggest hurdle to successful would be the immunosuppressive tumor microenvironment (TME) and low immunogenicity of cancer cells. To make successful, ‘cold’ TME must converted ‘hot’ immunostimulatory status activate residual host immune responses. this end, equilibrium should broken, immunogenic cell death ought induced stimulate tumor-killing cells appropriately. Photodynamic therapy (PDT) is an efficient way inducing (ICD) disrupting immune-restrictive tissues. PDT trigger a chain reaction that have ICD-induced antigens presented In principle, strategic combination synergize enhance therapeutic outcomes many intractable tumors. Novel technologies employing nanocarriers were developed deliver photosensitizers immunotherapeutic efficiently. New-generation nanomedicines been for recent years, which will accelerate clinical applications.

Language: Английский

---